This morning, after 16 years and $2.5 billion in investment, the Cambridge, Mass.-based company Alnylam finally turned a 1998 biology breakthrough into a medicine: a drug called Onpattro to treat the destruction of nerves that results from a rare disease thought to afflict about 50,000 people.
Alnylam Prices First Gene Silencing Drug At $450,000 Per Patient, But Offers Money-Back Guarantee
